Edition:
United Kingdom

Affimed NV (AFMD.OQ)

AFMD.OQ on NASDAQ Stock Exchange Global Market

3.21USD
19 Oct 2018
Change (% chg)

$-0.04 (-1.23%)
Prev Close
$3.25
Open
$3.25
Day's High
$3.30
Day's Low
$3.16
Volume
103,355
Avg. Vol
230,044
52-wk High
$7.35
52-wk Low
$1.17

Summary

Name Age Since Current Position

Thomas Hecht

2007 Chairman of the Supervisory Board

Adi Hoess

2011 Chief Executive Officer, Member of the Management Board

Florian Fischer

Chief Financial Officer, Member of the Management Board

Wolfgang Fischer

2018 Chief Operating Officer, Member of the Management Board

Martin Treder

2015 Chief Scientific Officer, Member of the Management Board

Leila Alland

2018 Member of the Management Board, Chief Medical Officer

Bernhard Ehmer

63 2016 Member of the Supervisory Board

Ulrich Grau

65 2015 Member of the Supervisory Board

Berndt Modig

58 2014 Member of the Supervisory Board

Richard Stead

2007 Member of the Supervisory Board

Ferdinand Verdonck

76 2014 Member of the Supervisory Board

Biographies

Name Description

Thomas Hecht

Dr. Thomas Hecht, M.D., has been Chairman of the Supervisory Board of Affimed N.V. since 2007. He is Head of Hecht Healthcare Consulting in Kuessnacht, Switzerland, a biopharmaceutical consulting company founded in 2002. Dr. Hecht also serves as Chairman of the Board of Directors of Cell Medica Ltd., Delenex AG, Vaximm AG and Aelix Therapeutics S.L. Until the beginning of March 2015, he served as Chairman of the Supervisory Council of SuppreMol GmbH. Dr. Hecht was previously Vice President Marketing at Amgen Europe. A seasoned manager and industry professional, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he was certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation at the University of Freiburg, Germany.

Adi Hoess

Dr. Adi Hoess, Ph.D., has been Chief Executive Officer and Member of the Management Board of Affimed N.V. since September 2011. Dr. Hoess joined Affimed in October 2010 as Chief Commercial Officer. He has more than 20 years of professional experience with an extensive background in general management, business development, product commercialization, fund raising and M&A. Prior to joining Affimed, Dr. Hoess was Chief Commercial Officer at Jerini AG and Chief Executive Officer of Jenowis AG. At Jerini AG he was responsible for BD and the market introduction of Firazyr. He also played a major role in the M&A process of Jerini AG with Shire. From 2000 – 2002 Dr. Hoess was General Manager and Vice President of the Molecular Medicine Division at Carl-Zeiss in Jena. Dr. Hoess began his professional career in 1993 at MorphoSys as scientist. In 1997 he became Director of BD and in 1999, Vice President of Licensing and BD. Dr. Hoess received his Ph.D. in chemistry and biochemistry from the University of Munich in 1991, and he also received an M.D. from the Technical University (TU) of Munich in 1997. From 1991 until 1993 he worked as a post doc at the Dana-Farber Cancer Institute at the Harvard Medical School in Boston, the United States.

Florian Fischer

Dr. Florian Fischer, Ph.D., serves as Chief Financial Officer and Member of the Management Board of Affimed N.V. Dr. Fischer joined Affimed in 2005 as Chief Financial Officer on a part-time basis. Since September 2014, Dr. Fischer is fulltime employed by Affimed. Dr. Fischer is founder of MedVenture Partners - a corporate finance and strategy advisory company focusing on the life sciences and healthcare industry. Dr. Fischer was Chief Financial Officer of Activaero GmbH from 2002 until 2011 and responsible for corporate development until the acquisition by Vectura in 2014. He also served as Chief Financial Officer of Vivendy Ltd. from 2008 until 2013 and as managing director of AbCheck in 2009. Prior to founding MedVenture Partners, Dr. Fischer worked with KPMG for more than six years until 2002, where he was responsible for biotech and healthcare assignments. Before joining KPMG, he worked for Deutsche Bank AG. Dr. Fischer is also a Director of Amphivena. He holds a graduate degree in business administration from Humboldt University, Berlin and a Ph.D. in public health from the University of Bielefeld.

Wolfgang Fischer

Dr. Wolfgang Fischer has been appointed Chief Operating Officer and Member of the Management Board of Affimed N.V. effective as of March 26, 2018. Prior to that, he has acted as Chief Operating Officer, Member of the Management Board and Interim Chief Medical Officer at the Company. He joined the Company in 2017 from Sandoz Biopharmaceuticals (Novartis Group). He has 20 years of experience in research and drug development with a focus on oncology, immunology and pharmacology. At Sandoz he managed the development and registration of Sandoz’ biosimilar pipeline assets since 2012 and served as Global Head of Program and Project Management since 2014. Prior to joining Sandoz, he held various positions of increasing responsibility within the Novartis Group since 2003, including Medical Director Oncology for Novartis Pharma Switzerland AG as well as Regional Medical Director Hematology (Emerging Growth Markets), where he was responsible for the Hematology Medical Affairs program and supported the launch of several products in various countries. He holds a Ph.D. in Cancer Research from the Swiss Federal Institute of Technology (ETH), Zurich, Switzerland. Thereafter, he completed postdoctoral fellowships at the Swiss Institute of Experimental Cancer Research, Lausanne, Switzerland and at the Scripps Research Institute, Department of Immunology, La Jolla, CA, USA, followed by a state doctorate (Habilitation) in Pharmacology and Toxicology at the Medical School of the University of Wuerzburg in Germany in 2003.

Martin Treder

Dr. Martin Treder has been Chief Scientific Officer and Member of the Management Board of Affimed N.V. since January 2015. He is responsible for the further development of Affimed’s proprietary bi- and trispecific TandAb platforms, the expansion of the company’s internal pipeline and furthermore providing scientific support for its clinical programs and for collaborations with corporate partners. Dr. Treder has 13 years of professional experience in the field of biotherapeutic research and development and broad experience in immuno-oncology discovery and pre-clinical development of antibodies. He joined the Affimed Management Team from CT Atlantic AG, a Swiss biotechnology company focused on the identification and development of human-derived monoclonal antibodies for the treatment of cancer. As co-founder and Chief Scientific Officer he was responsible for establishing a broad research pipeline of various preclinical and clinical development programs. Prior to CT Atlantic Dr. Treder was co-founder of U3 Pharma AG, a German biotech company developing targeted cancer therapeutics, and held the position of Program Director where he was responsible for heading the company’s portfolio of innovative anti-HER3 therapeutic antibodies. Dr. Treder graduated with Honors from Monash University in Melbourne, Australia and obtained a diploma in Biology at the University of Wuerzburg, Germany. He earned his Ph.D. working in Prof. Axel Ullrich's group at the Max Planck Institute of Biochemistry in Martinsried-Munich, Germany.

Leila Alland

Dr. Leila Alland has been appointed Member of the Management Board and Chief Medical Officer of Affimed N.V. effective as of March 26, 2018. She will be responsible for the clinical strategy and execution of Affimed’s first-in-class NK and T cell engager programs through early and late stage clinical trials. Dr. Alland brings to the Company over 20 years of experience in industry and academic research with a strong track record of successful oncology and hematology drug development. has broad experience as a clinical leader developing both large and small molecule oncology products for solid and hematological malignancies, including Opdivo, Tagrisso, and Tasigna. Dr. Alland most recently served as Chief Medical Officer of Tarveda Therapeutics, developing clinical candidates for solid tumors. Prior to that, she was Vice President and Head of Oncology Early Clinical Development at AstraZeneca where she led Phase 1 and Phase 2 clinical development of oncology and immuno-oncology programs including a Phase 2 registration study that contributed to the accelerated approval of Tagrisso. Previously, Dr. Alland served at Bristol-Myers Squibb as clinical head for multiple early phase oncology programs including immuno-oncology antibody therapeutics, and at Novartis where she led the clinical development program for Tasigna. Dr. Alland is also an experienced pediatric hematologist/oncologist and accomplished scientist, having served on the faculty at Albert Einstein College of Medicine, New York City, where she was awarded the prestigious James S. McDonnell Foundation Scholar Award for research. Dr. Alland completed her fellowship in pediatric hematology and oncology at Memorial Sloan Kettering Cancer Center, NY and her internship and residency at The Children’s Hospital of Philadelphia, PA. She received her B.A. from the University of Pennsylvania and her M.D. from New York University School of Medicine.

Bernhard Ehmer

Dr. Bernhard R. M. Ehmer has been Member of the Supervisory Board of Affimed N.V. since 2016. He has been Chairman of the Board of Management of Biotest AG since January 2015. Prior to this, he worked for the Imclone Group, a wholly owned subsidiary of Eli Lilly, as President of Imclone Systems Corporation in the United States and as managing director in Germany. In 2007/2008 he was CEO of Fresenius Biotech, Germany and before this, Dr. Ehmer headed the Business Area Oncology of Merck KGaA, Darmstadt and served as head of Global Clinical Operations at Merck. Between 1986 and 1998 he held various functions at Boehringer Mannheim in Germany, Italy and Singapore. Dr. Ehmer holds a degree in medicine and worked in the Department of Internal Medicine at the Academic Teaching Hospital of the University of Heidelberg.

Ulrich Grau

Dr. Ulrich M. (Uli) Grau, Ph.D., has been Member of the Supervisory Board of Affimed N.V. since July 2017. He served as an advisor to Affimed’s board from May 2013 until June 2015. He has over 30 years of experience in the biotechnology and pharmaceutical industries including general management, business development, corporate strategy and the development of new products and technologies. Dr. Grau was Chief Operating Officer at Micromet from 2011 to 2012. Between 2006 and 2010, Dr. Grau was a founder, President and CEO of Lux Biosciences, Inc., a clinical stage ophthalmic company. Previously, Dr. Grau served as President of Research and Development at BASF Pharma/Knoll where he directed a global R&D organization whose development pipeline included Humira. The majority of his career was at Aventis Pharma, where he last held the position of Senior VP of Global Late Stage Development. Lantus is based on his inventions made during his early years as a scientist with Hoechst AG. Dr. Grau received his Ph.D. in chemistry and biochemistry from the University of Stuttgart and spent three years as a post-doctoral fellow at Purdue University in the field of protein crystallography.

Berndt Modig

Mr. Berndt Modig has been Member of the Supervisory Board of Affimed N.V. since 2014. He has served as Chief Financial Officer of Prosensa Holding N.V. from March 2010 through January 2015 when Prosensa was acquired by BioMarin Pharmaceutical Inc. Mr. Modig also serves as member of the Board of Directors and Chairman of the Audit Committee of Auris Medical Holding AG and Axovant Sciences Ltd. Mr. Modig has more than 25 years of international experience in finance and operations, private equity and mergers and acquisitions. Before joining Prosensa, Mr. Modig was Chief Financial Officer at Jerini AG from October 2003 to November 2008, where he directed private financing rounds, its initial public offering in 2005 and its acquisition by Shire plc in 2008. Prior to Jerini, Mr. Modig served as Chief Financial Officer at Surplex AG from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc. from 1999 to 2001. In previous positions, Mr. Modig was a partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a senior manager in the financial services industry group of Price Waterhouse LLP in New York from 1991 to 1994. Mr. Modig served as a Director of Mobile Loyalty plc from 2012 to 2013. Mr. Modig has a bachelor’s degree in business administration, economics and German from the University of Lund, Sweden and an MBA degree from INSEAD, Fontainebleau, France and is a Certified Public Accountant.

Richard Stead

Dr. Richard B. Stead, M.D., has been Member of the Supervisory Board of Affimed N.V. since 2007. He has more than 25 years of experience in the biotechnology and pharmaceutical industries, designing and directing clinical trials, regulatory strategy and licensing activities. He is currently Founder and Principal of BioPharma Consulting Services, where he is involved in the development of a number of oncology products including different strategies for cancer immunotherapy. Previously, he was Vice President, Clinical Research of Immunex Corporation, responsible for oncology and neurology product development. Dr. Stead has served in various positions in clinical development and played a key role in the FDA approval and commercialization of Amgen’s first two products, Epogen and Neupogen. Dr. Stead graduated from the University of Wisconsin and earned an M.D. from Stanford University. He completed his internship and residency as well as a fellowship in hematology at Harvard Medical School and the Brigham and Women’s Hospital followed by post-doctoral research in the Laboratory of Molecular Biology at the National Cancer institute. He also serves on the boards of Ascend Biopharmaceuticals Ltd. and the Seattle Repertory Theatre.

Ferdinand Verdonck

Dr. Ferdinand L J Verdonck, J.D., has been Member of the Supervisory Board of Affimed N.V. since July 2014. He is Chair of the Audit Committee at the Company. He is a Director and Member of the Audit Committee of Virtus Funds and member of the Board of Laco Information Services. In recent years he was Chairman of the Supervisory Board of uniQure N.V., a member of the Board of Group SNEF and of J.P. Morgan European Investment Trust and a member of the Board of Directors and Chairman of the Audit Committee of two biotechnology companies in Belgium, Movetis and Galapagos. He has previously served as Chairman of Banco Urquijo and of Nasdaq Europe and as a Director of Dictaphone Corporation. From 1992 to 2003, he was the Managing Director of Almanij NV, a financial services company which has since merged with KBC, and his responsibilities included company strategy, financial control, supervision of executive management and corporate governance, including board participation in publicly-traded and privately-held companies in many countries. He holds a law degree from KU Leuven and degrees in economics from KU Leuven and the University of Chicago.